TW202317623A - 基於il2之治療劑及其使用方法 - Google Patents

基於il2之治療劑及其使用方法 Download PDF

Info

Publication number
TW202317623A
TW202317623A TW111121656A TW111121656A TW202317623A TW 202317623 A TW202317623 A TW 202317623A TW 111121656 A TW111121656 A TW 111121656A TW 111121656 A TW111121656 A TW 111121656A TW 202317623 A TW202317623 A TW 202317623A
Authority
TW
Taiwan
Prior art keywords
seq
fusion protein
amino acid
acid sequence
protein according
Prior art date
Application number
TW111121656A
Other languages
English (en)
Chinese (zh)
Inventor
吳家曦
尼可林 布洛赫
張彤
家楊 林
塞繆爾 戴維斯
艾瑞克 史密斯
艾麗卡 烏爾曼
Original Assignee
美商再生元醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商再生元醫藥公司 filed Critical 美商再生元醫藥公司
Publication of TW202317623A publication Critical patent/TW202317623A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW111121656A 2021-06-14 2022-06-10 基於il2之治療劑及其使用方法 TW202317623A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163210111P 2021-06-14 2021-06-14
US63/210,111 2021-06-14
US202263365375P 2022-05-26 2022-05-26
US63/365,375 2022-05-26

Publications (1)

Publication Number Publication Date
TW202317623A true TW202317623A (zh) 2023-05-01

Family

ID=82361286

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111121656A TW202317623A (zh) 2021-06-14 2022-06-10 基於il2之治療劑及其使用方法

Country Status (12)

Country Link
US (1) US12528851B2 (OSRAM)
EP (1) EP4355427A1 (OSRAM)
JP (1) JP2024521472A (OSRAM)
KR (1) KR20240021194A (OSRAM)
AU (1) AU2022292792A1 (OSRAM)
BR (1) BR112023023787A2 (OSRAM)
CL (2) CL2023003730A1 (OSRAM)
CO (1) CO2023015593A2 (OSRAM)
IL (1) IL308369A (OSRAM)
MX (1) MX2023014905A (OSRAM)
TW (1) TW202317623A (OSRAM)
WO (1) WO2022266598A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
US20230391844A1 (en) 2022-06-04 2023-12-07 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
WO2024014808A1 (ko) * 2022-07-11 2024-01-18 주식회사 지뉴브 사이토카인 융합 단백질
KR20250089551A (ko) * 2022-10-31 2025-06-18 리제너론 파마슈티칼스 인코포레이티드 입양 세포 요법과 표적 면역사이토카인을 조합하여 이용한 암 치료 방법
EP4491631A1 (en) * 2023-07-13 2025-01-15 Anaveon AG Anti-pd-1 antibody binding domain and immunoconjugate
EP4431525A1 (en) * 2023-03-16 2024-09-18 Anaveon AG Il-2 fusion protein
WO2025080540A1 (en) 2023-10-09 2025-04-17 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of a taaxcd3 bispecific antibody and a targeted immunocytokine
WO2025080538A1 (en) 2023-10-09 2025-04-17 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
WO2025218606A1 (zh) * 2024-04-16 2025-10-23 北京诺诚健华医药科技有限公司 抗体融合蛋白及其制备和应用

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1362062A (en) 1920-02-16 1920-12-14 American Sanitary Works Water-closet bowl
US2882777A (en) 1955-11-03 1959-04-21 Leland Gifford Co Hydraulic tracing apparatus
US3233920A (en) 1963-02-27 1966-02-08 Mueller Co Insulated pipe joint
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
ATE542137T1 (de) 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
ES2432141T3 (es) 2005-01-27 2013-11-29 Novartis Vaccines And Diagnostics, Inc. Procedimientos para tratar carcinoma de células renales
US9931413B2 (en) 2005-04-06 2018-04-03 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
PL1899364T5 (pl) 2005-05-17 2024-12-09 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
US20110274650A1 (en) 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
PE20120630A1 (es) 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
EP2553101A4 (en) 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2850575C (en) 2011-10-11 2020-12-15 Universitat Zurich Prorektorat Mnw Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
DK2859015T3 (en) 2012-06-08 2018-06-18 Alkermes Inc LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
MX2015016329A (es) 2013-05-28 2016-07-20 Dcb Usa Llc Bloqueador de anticuerpo para la inactivacion de farmaco de proteina.
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
GB2527075A (en) 2014-03-17 2015-12-16 Daassist As Percutaneous system, devices and methods
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
CA2991976A1 (en) * 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2017136818A2 (en) 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery
CA3013479A1 (en) 2016-02-16 2017-08-24 Carl NOVINA Immunotherapy compositions and methods
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
CN115073581A (zh) 2016-05-04 2022-09-20 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
EP3458485B1 (en) 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
SG11201903882VA (en) 2016-11-08 2019-05-30 Delinia Inc Il-2 variants for the treatment of autoimmune diseases
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
CN107082812B (zh) 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
EP4201953A1 (en) 2017-04-03 2023-06-28 F. Hoffmann-La Roche AG Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
JP7148539B2 (ja) 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
JP2020520671A (ja) 2017-05-24 2020-07-16 ノバルティス アーゲー 抗体−サイトカイングラフト化タンパク質及び使用方法
US20210277085A1 (en) 2017-05-24 2021-09-09 Pandion Therapeutics, Inc. Targeted immunotolerance
EP3634466A4 (en) 2017-06-06 2021-03-24 Relinia, Inc. MONOCATENARY TNF RECEPTOR 2 AGONIST FUSION PROTEINS
JP7433051B2 (ja) 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
CN111094330A (zh) 2017-07-03 2020-05-01 转矩医疗股份有限公司 编码免疫刺激融合分子的多核苷酸及其用途
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
PH12020550661A1 (en) 2017-11-21 2021-04-19 Univ Leland Stanford Junior Partial agonists of interleukin-2
BR112020011343A2 (pt) 2017-12-06 2020-11-17 Pandion Therapeutics, Inc. muteínas de il-2 e seus usos
JP2021505156A (ja) 2017-12-06 2021-02-18 パンディオン・オペレーションズ・インコーポレイテッド 標的化免疫寛容
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
AU2018390418B2 (en) 2017-12-19 2023-12-21 Xencor, Inc. Engineered IL-2 Fc fusion proteins
WO2019129053A1 (zh) 2017-12-26 2019-07-04 南京金斯瑞生物科技有限公司 以抗体Fc区为骨架的融合蛋白二聚体及其应用
WO2019166946A1 (en) * 2018-02-28 2019-09-06 Pfizer Inc. Il-15 variants and uses thereof
WO2019168791A2 (en) 2018-02-28 2019-09-06 The Board Of Trustees Of The Leland Stanford Junior University Single-chain il-2/antibody fusions that selectively activate regulatory t cells
CA3115461A1 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
KR102824112B1 (ko) * 2018-03-28 2025-06-24 브리스톨-마이어스 스큅 컴퍼니 인터루킨-2/인터루킨-2 수용체 알파 융합 단백질 및 사용 방법
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CU24554B1 (es) 2018-05-07 2021-11-04 Ct Inmunologia Molecular Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
CN113840832A (zh) 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
EP3810640A1 (en) 2018-06-25 2021-04-28 University of Washington De novo design of potent and selective interleukin mimetics
JP7550745B2 (ja) 2018-07-24 2024-09-13 バイオエヌテック エスエー Ｉｌ２アゴニスト
EP3876986A4 (en) 2018-09-18 2022-06-01 Pandion Operations, Inc. Targeted immunotolerance
EP3854805A4 (en) 2018-09-21 2022-08-24 Innovent Biologics (Suzhou) Co., Ltd. NOVEL INTERLEUKIN 2 AND ITS USE
EP3856229A1 (en) 2018-09-28 2021-08-04 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
CR20210239A (es) 2018-10-12 2021-12-15 Xencor Inc Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
AU2019401183A1 (en) 2018-12-19 2021-08-12 Cue Biopharma, Inc. Multimeric T-cell modulatory polypeptides and methods of use thereof
WO2020132368A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020132136A1 (en) 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP7797198B2 (ja) 2018-12-21 2026-01-13 オーエスイー・イミュノセラピューティクス ヒトｐｄ－１に対する二機能性分子
JP7762570B2 (ja) 2019-05-20 2025-10-30 サイチューン ファーマ 癌又は感染性疾患を処置するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト投薬レジメン
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
JP2022533254A (ja) 2019-05-24 2022-07-21 プロヴィヴァ セラピューティクス （ホン コン） リミテッド Ｉｌ－２組成物およびその使用方法
CA3142738A1 (en) * 2019-06-05 2020-12-10 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
US20220235109A1 (en) * 2019-06-14 2022-07-28 Cugene Inc Novel interleukin-2 variants for the treatment of cancer
CN114008082A (zh) 2019-06-24 2022-02-01 南京金斯瑞生物科技有限公司 单克隆抗体-细胞因子融合蛋白二聚体及其应用
AU2020315282B2 (en) 2019-07-12 2026-02-12 Proviva Therapeutics (Hong Kong) Limited IL-2 compositions and methods of use thereof
KR20220044834A (ko) 2019-08-15 2022-04-11 사이팀 테라퓨틱스, 인크. 변형된 인터루킨 2 (il-2) 폴리펩타이드, 컨쥬게이트 및 이의 용도
TW202124437A (zh) 2019-08-19 2021-07-01 美商潘迪恩營運公司 以ｐｄ－１促效劑進行之標靶免疫耐受性
WO2021055568A1 (en) 2019-09-19 2021-03-25 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
EP4107189A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
CN116390744A (zh) 2020-06-24 2023-07-04 梅迪塞纳医疗股份有限公司 双功能性超级因子及其用途
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法

Also Published As

Publication number Publication date
IL308369A (en) 2024-01-01
EP4355427A1 (en) 2024-04-24
WO2022266598A1 (en) 2022-12-22
AU2022292792A1 (en) 2024-01-04
KR20240021194A (ko) 2024-02-16
CL2023003730A1 (es) 2024-07-05
BR112023023787A2 (pt) 2024-02-20
US20220402989A1 (en) 2022-12-22
CO2023015593A2 (es) 2023-11-30
MX2023014905A (es) 2024-02-14
US12528851B2 (en) 2026-01-20
JP2024521472A (ja) 2024-05-31
CL2024003382A1 (es) 2025-03-28

Similar Documents

Publication Publication Date Title
US12528851B2 (en) IL2-based therapeutics and methods of use thereof
US12344672B2 (en) Antibody molecules that bind PD-L1 and CD137
JP7690552B2 (ja) ＣＤ１３７抗原結合部位を含むＦｃ結合断片
CN108884164B (zh) 用于免疫疗法的经修饰细胞
JP7489316B2 (ja) Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
JP7603205B2 (ja) 抗体分子
JP7474235B2 (ja) ＯＸ４０抗原結合部位を含むＦｃ結合断片
TW202400654A (zh) 抗tigit抗體及其作為治療和診斷的用途
JP2020518622A (ja) Ｏｘ４０およびｃｔｌａ−４に対する二重特異性抗体
KR20190130137A (ko) 종양 특이적 세포 고갈을 위한 fc-최적화된 항-cd25
JP2018520650A (ja) 新規のポリペプチド
JP7674278B2 (ja) 抗ニューヨーク食道扁平上皮がん１（ｎｙ－ｅｓｏ－１）抗原結合タンパク質およびその使用方法
WO2020229844A1 (en) Binding molecules
JP2024534838A (ja) ＮＫｐ４６結合ポリペプチド及びその使用
CN116194471A (zh) 抗pd-1抗体和融合蛋白
TW202200615A (zh) 用於治療和預防患者的crs之方法
CN117940462A (zh) 基于il2和抗pd-1的双特异性治疗及其使用方法
CA3171061A1 (en) Il2-based therapeutics and methods of use thereof
EA052561B1 (ru) Терапевтические средства на основе il-2 и анти-pd-1 и способы их применения
TWI835166B (zh) 靶向pd-1和/或ox40的特異性結合蛋白及其應用
US20250114469A1 (en) METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAxCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINE
WO2026103838A1 (en) Polypeptide complexes comprising il-21 variants and uses thereof
US20250114468A1 (en) Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
CN114605538A (zh) 靶向cd19的人源化抗体及其用途